Agilent Technologies Inc. announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable […]
Post Type Archives: News
SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd., a fully integrated biopharmaceutical company and subsidiary of Shilpa Medicare Limited, announce a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across the region […]
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Genetix Biotherapeutics Inc. (Genetix), a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced the extension of their long-term commercial manufacturing agreement. Under the expanded agreement, Lonza will expand manufacturing capacity to support growing demand […]
Neuland to open commercial peptide facility as part of planned phased expansion
Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases. The first of four planned modules is expected to be operational by the summer of this year, adding commercial-scale capabilities to Neuland’s existing clinical stage S-Block facilities. […]
GSK and Alfasigma announce agreement on worldwide rights for linerixibat
GSK plc and Alfasigma S.p.A. announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC). Alfasigma is a global pharmaceutical company with established capabilities in specialty care and rare […]
Servier Acquires Day One Biopharmaceuticals for $2.5 Billion
Servier, an independent international pharmaceutical group, and Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company advancing treatments for pediatric cancers, announced a definitive acquisition agreement on March 6, 2026. Servier will acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The deal is expected to close in […]
Biologos Appoints Hetal Patel as Chief Executive Officer, Celebrates 50 Years of Growth and Innovation
Biologos, a leading ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as Chief Executive Officer. The announcement coincides with Biologos’ 50th anniversary and follows significant recent investments in facilities and capabilities to support customers across biopharma, cell and gene therapy (CGT), tissue processing, and animal health […]
FDA Approves Johnson & Johnson Second-Line Multiple Myeloma Treatment
Johnson & Johnson announced FDA approval of Tecvayli (teclistimab-cqyv) plus Darzalex Faspro (daratumumab and haluronidase-fihj) as a treatment for relapsed or refractory multiple myeloma (RRMM) on March 5th, 2026. The treatment is indicated for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, according to […]
CordenPharma Colorado Partners with BioMed Realty on Peptide Development Lab Expansion at Flatiron Park in Boulder
BioMed Realty and CordenPharma Colorado Team Up for Expansion of Peptide Development Lab in New LEED® Gold-Certified Facility at Flatiron Park in Boulder Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development BioMed Realty, the largest private owner and operator of real estate for the life science, […]
Completion of the Acquisition of Innovis Pharma by PharmaPath
PharmaPath and Innovis Pharma are pleased to announce the successful completion of the acquisition of Innovis Pharma by PharmaPath, following an initial agreement signed in December 2025. This strategic milestone, sets new standards for both companies, marking the creation of a new fully integrated Greek pharmaceutical group with more than 450 employees, combining advanced expertise […]